theMednetRegister

General Internal Medicine

NCI-CCC Tumor Board Question   

These are questions being discussed by academics at NCI-Cancer Centers

Questions discussed in this category

What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
1 Answer available
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
2 Answers available
What is your approach for using anticoagulation/aspirin in patients with multiple myeloma?
2 Answers available
How would you approach a patient with imaging and labs suggestive of potentially resectable cholangiocarcinoma when several core biopsies reveal bridging fibrosis with no malignant cells?
1 Answer available
What infectious prophylaxis do you use for patients with newly diagnosed multiple myeloma?
How do you decide how long to continue?
1 Answer available
How does one interpret persistently positive lambda light chains on serum immunofixation but without measurable serum monoclonal protein and a normal light chains and ratio?
Is a repeatedly abnormal serum immunofixation all it takes for MGUS?
2 Answers available
In patients with inflammatory bowel disease with low rectal cancer with planned proctocolectomy, would you consider creation of a pouch?
1 Answer available
How has COVID-19 altered your recommendations for invasive mediastinal staging for NSCLC?
Should staging and treatment decisions be made based on imaging alone?
2 Answers available
Should breast cancer patients with never-treated latent TB and for whom chemotherapy is indicated be treated for latent TB during chemotherapy?
2 Answers available
What is the preferred clinical management of hyperglycemia related to alpelisib?
1 Answer available
How would you approach a biopsy proven NSCLC patient with mediastinum negative disease and contralateral suspicious spiculated PET avid nodule without pathologic diagnosis?
No other site of metastatic disease. It is unclear if this situation should be managed as two separate primaries or metastatic disease.
2 Answers available
How do you manage a patient with multiple similar appearing ground glass opacities (~8-9) on Chest CT where one has been surgically removed and confirmed to be adenocarcinoma in situ?
There is no evidence of disease outside the lung on PET, and the patient is completely asymptomatic with negative EGFR, ALK, ROS1, and BRAF and a PD-L...
1 Answer available
How would you approach the management of a patient with oligometastatic NSCLC characterized by a LUL mass and a solitary adrenal metastasis, assuming a good performance status?
1 Answer available


Papers discussed in this category

The Lancet. Oncology, 2016-12
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
The New England journal of medicine, 2012-02-09
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
N. Engl. J. Med.,
Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Lancet Oncol, 2019 Oct 23
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Br J Haematol, 2021 Aug 15
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Blood, 2022 Dec 08
Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score.
JAMA, 2023 Aug 8
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Blood, 2017 Jan 31
Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.

Related Topics in General Internal Medicine

Copyright © 2025 theMednet
All Rights Reserved.